CEL-SCI completes $10 million stock offering for drug development

CEL-SCI Corporation (NYSE American: CVM) closed a public offering of 1,111,200 common shares at $9.00 per share, generating approximately $10 million in gross proceeds before fees and expenses.

The clinical stage cancer immunotherapy company plans to use the net proceeds to fund continued development of Multikine, its investigational cancer treatment, along with general corporate purposes and working capital.

ThinkEquity served as the sole placement agent for the offering. The securities were sold under a shelf registration statement filed with the Securities and Exchange Commission on July 3, 2025, and declared effective on August 12, 2025.

Multikine is designed as a neoadjuvant therapy administered before surgery to help patients' immune systems target tumors. The treatment has been dosed in over 740 patients and received Orphan Drug designation from the FDA for patients with squamous cell carcinoma of the head and neck.

The Vienna, Virginia-based company operates facilities in Virginia and near Baltimore, Maryland. Multikine has not been approved by the FDA or any other regulatory agency for commercial use.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• enVVeno Medical (NVNO) files $100M mixed shelf
• RenovoRx regains Nasdaq minimum bid price compliance